Home
Clinical Trials
Epoetin Alfa With or Without ...

Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer

Last Updated: 2023-06-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

282 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Epoetin alfa may stimulate red blood cell production and may help improve cancer-related anemia and fatigue. Steroid therapy with dexamethasone may increase the effectiveness of epoetin alfa. It is not yet known if epoetin alfa is more effective with or without dexamethasone in treating anemia-related fatigue in patients with prostate cancer.

PURPOSE: This randomized phase III trial is studying epoetin alfa and dexamethasone to see how well they work compared to epoetin alfa alone in treating anemia-related fatigue in patients with prostate cancer that is refractory to treatment with hormone therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00010231

Prostate Cancer

COMPLETED PHASE1

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00524589

Prostate Cancer

TERMINATED PHASE2

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy

NCT00054522

Prostate Cancer

COMPLETED PHASE2

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06592924

Prostate Cancer (Adenocarcinoma)

RECRUITING PHASE3

Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer

NCT00255606

Prostate Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Compare the effect of epoetin alfa with or without dexamethasone on the level of cancer-related fatigue measured by the FACIT fatigue subscale, in patients with hormone-refractory prostate cancer.
* Compare the effect of these regimens on increasing hemoglobin levels in these patients.
* Compare the effect of these regimens on palliation of other disease-related symptoms and on functional status and overall quality of life of these patients.
* Compare the survival rate of these regimens in these patients.
* Compare the toxicity profile of these regimens in these patients.
* Determine the incidence of adrenal suppression in these patients after receiving dexamethasone therapy.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to usual fatigue severity on the Brief Fatigue Inventory numerical scale (3-6 vs 7-10) and hemoglobin level (8-10 g/dL vs 10.1-11.9 g/dL). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive epoetin alfa subcutaneously once a week.
* Arm II: Patients receive epoetin alfa as in arm I and oral dexamethasone once a day.

In both arms, treatment continues for 12 weeks in the absence of unacceptable toxicity.

Quality of life and fatigue are assessed at baseline and then at 4, 8, and 12 weeks.

Patients are followed for 3 years.

PROJECTED ACCRUAL: A total of 282 patients (141 per treatment arm) will be accrued for this study within approximately 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia Fatigue Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

SUPPORTIVE_CARE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

epoetin alfa

Intervention Type BIOLOGICAL

dexamethasone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed prostate cancer

* Hormone-refractory disease as evidenced by progression on bone scan or CT scan with a rising prostate-specific antigen
* Prior bilateral orchiectomy OR other primary hormonal therapy (e.g., estrogen therapy or luteinizing hormone-releasing hormone analog \[LHRH\] and flutamide) with evidence of treatment failure

* Concurrent continual LHRH agonist therapy (e.g., depot leuprolide or goserelin) required for patients who have not undergone bilateral orchiectomy
* Must have anemia with hemoglobin ≥ 8 g/dL and \< 12 g/dL within the past 14 days
* Must be iron replete (i.e., ferritin \> 50 ng/mL) within the past 30 days
* Presence of fatigue with usual fatigue severity ≥ 3 on the 0-10 numerical scale of the Brief Fatigue Inventory within the past 14 days

PATIENT CHARACTERISTICS:

Age

* 18 and over

Performance status

* ECOG 0-3

Life expectancy

* Not specified

Hematopoietic

* See Disease Characteristics
* No disseminated intravascular coagulation
* No autoimmune hemolytic anemia

Hepatic

* AST and ALT ≤ 2 times upper limit of normal
* No prior hemochromatosis or iron intolerance

Renal

* Creatinine \< 2.5 mg/dL

Cardiovascular

* Adequate blood pressure (i.e., systolic blood pressure \< 140 mm Hg and diastolic blood pressure \< 90 mm Hg) (treated or untreated)
* No history of thromboembolic events
* No unstable angina
* No poorly controlled cardiac disease

Other

* Fertile patients must use effective contraception
* Able to read, understand, and answer questions on the symptom and quality of life study instruments
* No ongoing chronic hemorrhage (e.g., gross hematuria due to advanced prostate cancer)\* NOTE: \*Microscopic hematuria allowed
* No acute or subacute illness that may require transfusion
* No gastrointestinal bleeding
* No active systemic infection
* No known or suspected hypersensitivity to human albumin
* No known or suspected hypersensitivity to mammalian cell-derived products
* No uncontrolled diabetes

PRIOR CONCURRENT THERAPY:

Biologic therapy

* More than 30 days since prior epoetin alfa

Chemotherapy

* More than 21 days since prior chemotherapy
* No more than 2 different types of prior chemotherapy regimens for hormone-refractory prostate cancer

Endocrine therapy

* See Disease Characteristics
* More than 30 days since prior corticosteroids for hormone-refractory prostate cancer

* Episodic use of low-dose steroids for other causes is allowed

Radiotherapy

* More than 21 days since prior radiotherapy
* Concurrent radiotherapy allowed

Surgery

* See Disease Characteristics

Other

* More than 8 weeks since prior blood transfusion
* No concurrent oral or intravenous antibiotics

Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shirley S. Hwang, RN, MS

Role: STUDY_CHAIR

Veterans Affairs Medical Center - East Orange

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Memorial Medical Center Cancer Services

Modesto, California, United States

Site Status

Aurora Presbyterian Hospital

Aurora, Colorado, United States

Site Status

Boulder Community Hospital

Boulder, Colorado, United States

Site Status

Penrose Cancer Center at Penrose Hospital

Colorado Springs, Colorado, United States

Site Status

Porter Adventist Hospital

Denver, Colorado, United States

Site Status

Presbyterian - St. Luke's Medical Center

Denver, Colorado, United States

Site Status

St. Joseph Hospital

Denver, Colorado, United States

Site Status

Rose Medical Center

Denver, Colorado, United States

Site Status

CCOP - Colorado Cancer Research Program, Incorporated

Denver, Colorado, United States

Site Status

Swedish Medical Center

Englewood, Colorado, United States

Site Status

Sky Ridge Medical Center

Lone Tree, Colorado, United States

Site Status

Hope Cancer Care Center at Longmont United Hospital

Longmont, Colorado, United States

Site Status

St. Mary-Corwin Regional Medical Center

Pueblo, Colorado, United States

Site Status

North Suburban Medical Center

Thornton, Colorado, United States

Site Status

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

Tampa, Florida, United States

Site Status

Winship Cancer Institute of Emory University

Atlanta, Georgia, United States

Site Status

Veterans Affairs Medical Center - Atlanta (Decatur)

Decatur, Georgia, United States

Site Status

Rush-Copley Cancer Care Center

Aurora, Illinois, United States

Site Status

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Chicago, Illinois, United States

Site Status

Hematology and Oncology Associates

Chicago, Illinois, United States

Site Status

Veterans Affairs Medical Center - Lakeside Chicago

Chicago, Illinois, United States

Site Status

Mercy Hospital and Medical Center

Chicago, Illinois, United States

Site Status

Swedish Covenant Hospital

Chicago, Illinois, United States

Site Status

St. Anthony's Memorial Hospital

Effingham, Illinois, United States

Site Status

Elmhurst Memorial Hospital

Elmhurst, Illinois, United States

Site Status

Hinsdale Hematology Oncology Associates

Hinsdale, Illinois, United States

Site Status

Midwest Center for Hematology/Oncology

Joliet, Illinois, United States

Site Status

Joliet Oncology-Hematology Associates, Limited - West

Joliet, Illinois, United States

Site Status

North Shore Oncology and Hematology Associates, Limited - Libertyville

Libertyville, Illinois, United States

Site Status

Northwest Medical Specialist, PC

Niles, Illinois, United States

Site Status

Hematology/Oncology of the North Shore at Gross Point Medical Center

Skokie, Illinois, United States

Site Status

Midwest Cancer Research Group, Incorporated

Skokie, Illinois, United States

Site Status

Carle Cancer Center at Carle Foundation Hospital

Urbana, Illinois, United States

Site Status

CCOP - Carle Cancer Center

Urbana, Illinois, United States

Site Status